Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

Talk:25H-NBOMe: Difference between revisions

From PsychonautWiki Archive
Jump to navigation Jump to search
>Dextromethorphan
some info
>Dextromethorphan
cleaned up article
Line 88: Line 88:
The visual geometry produced by this substance is similar to [[LSD]] and can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colorful in scheme, glossy in color, sharp around the edges and equally angular as well as rounded across their corners. In comparison to other more commonly used psychedelics they can be described as significantly more intricate than the visual geometry found within [[2C-I]] and most of the [[2C-x]] family in general as well as completely on par with [[LSD]], [[Psilocin]] and [[DMT]] at appropriately high dosages.  
The visual geometry produced by this substance is similar to [[LSD]] and can be comprehensively described as algorithmic in geometric style, intricate in complexity, fine and zoomed out in detail, fast and smooth in motion, structured in shape, colorful in scheme, glossy in color, sharp around the edges and equally angular as well as rounded across their corners. In comparison to other more commonly used psychedelics they can be described as significantly more intricate than the visual geometry found within [[2C-I]] and most of the [[2C-x]] family in general as well as completely on par with [[LSD]], [[Psilocin]] and [[DMT]] at appropriately high dosages.  


25I-NBOMe’s geometry leads reliably leads to [[Effect::8A Geometry|Level 8A]] visual geometry with [[Level 8B]] remaining so far unconfirmed. It seems to consistently be able to build up in visual intensity when the user stares at a central point. This eventually envelops the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.
25H-NBOMe’s geometry leads reliably leads to [[Effect::8A Geometry|Level 8A]] visual geometry with [[Level 8B]] remaining so far unconfirmed. It seems to consistently be able to build up in visual intensity when the user stares at a central point. This eventually envelops the visual field and creates the sensation that the tripper has broken through into a continuously shifting geometric landscape or structure with a vast sense of immersive physical size attributed to it.


====Hallucinatory states====
====Hallucinatory states====
25I-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 hallucinatory breakthroughs are reported but very different and inconsistent in comparison to other more commonly used psychedelics such as [[psilocin]], [[2C-E]] and [[DMT]].
25H-NBOMe is capable of producing a full range of hallucinatory states within the level 1 - 3 range extremely consistently. However, level 4 hallucinatory breakthroughs are reported but very different and inconsistent in comparison to other more commonly used psychedelics such as [[psilocin]], [[2C-E]] and [[DMT]].


These effects include:
These effects include:
Line 102: Line 102:
|{{effects/cognitive|
|{{effects/cognitive|


The cognitive effects of 25I-NBOMe are described by many as notably light in comparison to the classical [[psychedelics]]. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, strong to overwhelming cognitive alterations become present, which can lead to states of [[confusion]], [[amnesia]], and general sensory overload.  
The cognitive effects of 25H-NBOMe are described by many as notably light in comparison to the classical [[psychedelics]]. It is not uncommon for people to report feeling that their thought stream has maintained general normality in its specific style throughout low to moderate dosages. At high dosages, however, strong to overwhelming cognitive alterations become present, which can lead to states of [[confusion]], [[amnesia]], and general sensory overload.  


The most prominent of these cognitive effects generally include:
The most prominent of these cognitive effects generally include:


*'''[[Effect::Analysis enhancement]]''' - This effect is generally only present at low doses.
*'''[[Effect::Analysis enhancement]]''' - This effect is generally only present at low doses.
*'''[[Effect::Thought acceleration]]''' and '''[[Effect::Thought deceleration]]''' - Although one of 25i-NBOME's effects is thought acceleration, the opposite may occur at higher doses.
*'''[[Effect::Thought acceleration]]''' and '''[[Effect::Thought deceleration]]''' - Although one of 25H-NBOME's effects is thought acceleration, the opposite may occur at higher doses.
*'''[[Effect::Conceptual thinking]]''' - This effect is considered to be very mild compared to traditional psychedlics.
*'''[[Effect::Conceptual thinking]]''' - This effect is considered to be very mild compared to traditional psychedlics.
*'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect seems to occur more readily than other psychedelics, perhaps due to its very prominent stimulating properties
*'''[[Effect::Anxiety]]''' & '''[[Effect::Paranoia]]''' - This effect seems to occur more readily than other psychedelics, perhaps due to its very prominent stimulating properties
Line 150: Line 150:
===Experience reports===
===Experience reports===
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
Anecdotal reports which describe the effects of this compound within our [[experience index]] include:
{{#ask: [[Category:25I-NBOMe]][[Category:Experience]]|format=ul|Columns=1}}
{{#ask: [[Category:25H-NBOMe]][[Category:Experience]]|format=ul|Columns=1}}
Additional experience reports can be found here:
Additional experience reports can be found here:


*[https://www.erowid.org/experiences/subs/exp_25INBOMe.shtml Erowid Experience Vaults: 25I-NBOMe]
<!-- *[https://www.erowid.org/experiences/subs/exp_25INBOMe.shtml Erowid Experience Vaults: 25H-NBOMe] -->
*[https://erowid.org/experiences/exp.php?ID=102545 Erowid Experience: 25H-NBOMe]


==Toxicity and harm potential==
==Toxicity and harm potential==
Line 159: Line 160:
'''Short-term as well as long-term damage of NBOMes have been occasionally tied to serious physical and mental problems on seemingly random people, including memory and speech difficulties, heart problems, HPPD and in some cases Anxiety and PTSD, from particularly difficult experiences.'''
'''Short-term as well as long-term damage of NBOMes have been occasionally tied to serious physical and mental problems on seemingly random people, including memory and speech difficulties, heart problems, HPPD and in some cases Anxiety and PTSD, from particularly difficult experiences.'''


25I-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The [[LD50|LD<sub>50</sub>]] has not yet been determined although it is [[Toxicity::potentially fatal at heavy dosages]].<ref>"Fatalities / Deaths". Erowid. April 26, 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml</ref> [[PsychonautWiki]] advises that due to 25I-NBOMe's extreme potency it should not be insufflated as this method of administration appears to have led to several deaths in the past year.<ref>http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml/</ref>
25H-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The [[LD50|LD<sub>50</sub>]] has not yet been determined although it is [[Toxicity::potentially fatal at heavy or very heavy dosages]].<ref>"Fatalities / Deaths". Erowid. April 26, 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml</ref><ref>https://erowid.org/chemicals/nbome/nbome_death.shtml</ref> [[PsychonautWiki]] advises that due to 25H-NBOMe's extreme potency it should not be insufflated as this method of administration appears to have led to several related deaths in the past year.<ref>http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml/</ref>


This substance came to media attention in early 2012 after a cluster of seven non-fatal [[overdose]]s with the drug were reported in or around Richmond, Virginia.<ref name="Kids overdosing on new drug"> "Kids overdosing on new drug. Laura Geller, WWBT NBC12, Feb 18, 2012 | http://www.nbc12.com/story/16964534/kids-overdosing-on-new-drug</ref><ref name="New street drug"> New street drug causing concern among medics. Vanessa Araiza, WBRC, Feb 28, 2012, | http://www.wsfa.com/story/16977573/new-street-drug-causing-concern-among-medics</ref> As of May 2013, 25I-NBOMe has reportedly led to five overdose deaths in the United States.<ref> New drug N-bomb hits the street, terrifying parents, troubling cops | http://www.nydailynews.com/news/national/new-synthetic-hallucinogen-n-bomb-killing-users-cops-article-1.1336327</ref> In June 2012, two teens in Grand Forks, North Dakota and East Grand Forks, Minnesota fatally overdosed on a substance that was allegedly 25I-NBOMe, resulting in lengthy sentences for two of the parties involved and a Federal indictment against the Texas-based online vendor.<ref> Breaking Bad: Digital Drug Sales, Analog Drug Deaths. Craig Malisow, Houston Press, March 13, 2013 | http://www.houstonpress.com/2013-03-14/news/motion-research-charles-carlton/</ref>
The addition of 5-HTP can greatly increase the effects of 25H-NBOME and should be avoided.{{citation needed}}
 
A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for "several hours" beforehand. It is unclear what other drugs he may have consumed, as autopsies usually do not test for the presence of research chemicals.<ref name="21 yr old dies"> 21-year-old dies after one drop of new synthetic drug at Voodoo Fest. Naomi Martin, NOLA, November 1, 2012 | http://www.nola.com/crime/index.ssf/2012/11/21-year-old_dies_after_one_dro.html#incart_m-rpt-2/</ref>
 
A man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe.<ref name="Australia death"> New hallucinogenic drug 25B-NBOMe and 25I-NBOMe led to South Australian man's bizarre death | http://www.adelaidenow.com.au/news/south-australia/new-hallucinogenic-drug-25b-nbome-and-25i-nbome-led-to-south-australian-mans-bizarre-death/story-e6frea83-1226472672220/</ref>
 
A Brazilian 16-year-old died from overdose in April 2016.{{citation needed}}
 
The addition of 5-HTP can greatly increase the effects of 25i-NBOME and should be avoided.{{citation needed}}


It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance.
It is strongly recommended that one use [[responsible drug use|harm reduction practices]] when using this substance.


===Tolerance and addiction potential===
===Tolerance and addiction potential===
25I-NBOMe is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating.  
25H-NBOMe is [[Addiction potential::not habit-forming]] and the desire to use it can actually decrease with use. It is most often self-regulating.  


Tolerance to the effects of 25I-NBOMe is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::1 week]] for the tolerance to be reduced to half and [[Time to zero tolerance::2 weeks]] to be back at baseline (in the absence of further consumption). 25I-NBOMe presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 25I-NBOMe all psychedelics will have a reduced effect.
Tolerance to the effects of 25H-NBOMe is built [[Time to full tolerance::almost immediately after ingestion]]. After that, it takes about [[Time to half tolerance::1 week]] for the tolerance to be reduced to half and [[Time to zero tolerance::2 weeks]] to be back at baseline (in the absence of further consumption). 25H-NBOMe presents cross-tolerance with [[Cross-tolerance::all [[psychedelic]]s]], meaning that after the consumption of 25H-NBOMe all psychedelics will have a reduced effect.


===Overdose===
===Overdose===
Line 187: Line 180:


==Legal status==
==Legal status==
In September 2014, the European Council decided that 25I-NBOMe shall be subjected by the Member States to control measures and criminal penalties by October 2, 2015.<ref>{{cite web|url=https://op.europa.eu/o/opportal-service/download-handler?identifier=025bb164-4937-11e4-a0cb-01aa75ed71a1&format=pdfa1a&language=en&productionSystem=cellar&part=|title=Council Implementing Decision on subjecting 25I-NBOMe, AH-7921, MDPV and methoxetamine to control measures|date=September 25, 2014|publication-date=October 1, 2014|work=Official Journal of the European Union|pages=22-26|id=L 287|publisher=Office for Official Publications of the European Communites|oclc=52224955}}</ref>


*'''Australia''': Possession, production and sale is illegal.{{citation needed}}
*'''Canada''': 25H-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>
*'''Austria''': Since June 26, 2019, 25I-NBOMe is illegal to possess, produce and sell under the SMG. (Suchtmittelgesetz Österreich)<ref>https://www.ris.bka.gv.at/Dokumente/BgblAuth/BGBLA_2019_II_167/BGBLA_2019_II_167.pdfsig</ref>
*'''Switzerland''': 25H-NBOMe is a controlled substance defined as a derivative of N-benzylphenethylamine under Verzeichnis E point 130 and 131.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''Brazil''': Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.<ref>http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7</ref>
*'''United Kingdom''': 25H-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made</ref>
*'''Canada''': 25I-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.<ref>Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28</ref>
*'''United States''': 25H-NBOMe can be controlled under the Federal Analog act.
*'''China''': As of October 2015 25I-NBOMe is a controlled substance in China.<ref>http://www.sfda.gov.cn/WS01/CL0056/130753.html | 关于印发《非药用类麻醉药品和精神药品列管办法》的通知 </ref>
*'''Denmark''': 25I-NBOMe is controlled by the generic classification of phenethylamines in the Executive Order on Euphoriant Substances.<ref name="EMCDDA">{{cite web|url=http://www.emcdda.europa.eu/system/files/publications/817/TDAS14003ENN_466654.pdf|title=25I-NBOMe: EMCDDA–Europol Joint Report on a new psychoactive substance: 25I-NBOMe (4-iodo-2,5-dimethoxy-N-(2-methoxybenzyl)phenethylamine)|publisher=European Monitoring Centre for Drugs and Drug Addiction|access-date=February 18, 2020|issn=1977-7868|year=2014|isbn=978-92-9168-682-7|doi=10.2810/27828}}</ref>
*'''Germany''': 25I-NBOMe is controlled under Anlage I BtMG (''Narcotics Act, Schedule I'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html|title=Anlage I BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 11, 2019|language=de}}</ref> as of December 13, 2014.<ref>{{cite web|url=https://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl114s1999.pdf#__bgbl__%2F%2F*%5B%40attr_id%3D%27bgbl114s1999.pdf%27%5D__1576023093735|title=Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|access-date=December 11, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 11, 2019|language=de}}</ref>
*'''Finland''': 25I-NBOMe is controlled under the Medicines Act (395/87) as of March 15, 2013.<ref name="EMCDDA"></ref>
*'''Hungary''': 25I-NBOMe falls within the generic definition of phenethylamines in Schedule C of Government Decree 66/2012.<ref name="EMCDDA"></ref>
*'''Israel''': The drug was banned in 2012.<ref>http://www.health.gov.il/LegislationLibrary/25574413.pdf</ref>
*'''Italy''': In Italy 25I-NBOMe is a Schedule 1 controlled substance, meaning it's illegal in this state.<ref>Tabella 1 Stupefacenti dello Stato Italiano |http://www.salute.gov.it/imgs/C_17_pagineAree_3729_listaFile_itemName_0_file.pdf</ref>
*'''Latvia''': 25I-NBOMe is a Schedule I controlled substance.<ref>Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2,5-Dimetoksifeniletānamīni) | http://likumi.lv/doc.php?id=121086</ref>
*'''New Zealand''': 25I-NBOMe is a Schedule 2 controlled substance in New Zealand.<ref>http://www.legislation.govt.nz/act/public/1975/0116/latest/whole.html#DLM436576</ref>
*'''Norway''': 25I-NBOMe is controlled by the generic scheduling of phenethylamines as of February 14, 2013.<ref name="EMCDDA"></ref>
*'''Poland''': 25I-NBOMe falls under the definition of a ‘substitution drug’ under the Act on Counteracting Drug Addiction and the Act on State Sanitary Inspection, 2010. As such its marketing and production is penalised with a fine (administrative sanctions).<ref name="EMCDDA"></ref>
*'''Romania''': In 2011, Romania banned all psychoactive substances,<ref>http://drogriporter.hu/node/2211</ref> no matter what they really are.<ref>http://www.dreptonline.ro/legislatie/legea_194_2011_comba</ref>
*'''Russia''': Possession, production and sale is illegal.{{citation needed}}
*'''Slovenia''': 25I-NBOMe was included in a Decree amending the classification of illicit drugs (Official Gazette of RS No. 62/2013).<ref name="EMCDDA"></ref>
*'''Sweden''': 25I-NBOMe is classed as Schedule I.<ref>Läkemedelsverkets författningssamling - http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf</ref>
*'''Switzerland''': 25I-NBOMe is a controlled substance specifically named under Verzeichnis D.<ref>{{cite web|url=https://www.admin.ch/opc/de/classified-compilation/20101220/index.html|title=Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien|publisher=Bundeskanzlei [Federal Chancellery of Switzerland]|access-date=January 1, 2020|language=de}}</ref>
*'''United Kingdom''': 25I-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.<ref>United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made</ref>
*'''United States''': On Nov 15, 2013, the DEA added 25I-NBOMe to Schedule I using their emergency scheduling powers, making it "temporarily" in Schedule I for 2 years.<ref>http://www.justice.gov/dea/divisions/hq/2013/hq111513.shtml</ref>


==See also==
==See also==
Line 219: Line 193:
*[[Phenethylamines]]
*[[Phenethylamines]]
*[[25x-NBOMe]]
*[[25x-NBOMe]]
*[[25C-NBOMe]]
*[[25I-NBOMe]]
*[[25B-NBOMe]]


==External links==
==External links==


*[https://en.wikipedia.org/wiki/25I-NBOMe 25I-NBOMe (Wikipedia)]
*[https://en.wikipedia.org/wiki/25H-NBOMe 25H-NBOMe (Wikipedia)]
*[https://erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml 25I-NBOMe (Erowid Vault)]
*[https://isomerdesign.com/PiHKAL/search.php?domain=pk&id=5386 25H-NBOMe (Isomer Design)]
*[https://isomerdesign.com/PiHKAL/explore.php?id=5380 25I-NBOMe (Isomer Design)]
 
===Discussion===
 
*[http://disregardeverythingisay.com/post/49302181054/25i-nbome-broken-down-and-described 25I-NBOMe, broken down and described (Disregard Everything I Say)]


==References==
==References==
Line 246: Line 214:
|R2=
|R2=
|R3=OCH₃
|R3=OCH₃
|R4=I
|R4=
|R5=
|R5=
|R6=OCH₃
|R6=OCH₃
}}
}}

Revision as of 08:36, 8 October 2021


25I-NBOMe can be fatal at heavy doses.[1]

It is strongly discouraged to take large amounts of this substance or to insufflate (snort) it. Please see this section for more details.

Summary sheet: 25H-NBOMe

Template:SubstanceBox/25H-NBOMe

25H-NBOMe (also known as 2C-H-NBOMe, NBOMe-2C-H) is a novel psychedelic substance of the phenethylamine chemical class that produces an array of visually-dominant and stimulating psychedelic effects when administered.

It is worth noting that compounds of the NBOMe family should be administered sublingually by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes.

Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25H-NBOMe in humans. It had no history of human use before being sold online as a designer drug.[citation needed]. It has not officially been associated with fatalities liike more common members of the 25x-NBOMe family, possibly due to it never have been distributed as much. Anecdotal reports suggest that this substance may still be difficult to use safely due to its highly sensitive dose-response and unpredictable effects. It should be worth mentioning, that 25H-NBOMe, according to it's pharmacology might suggest that it might possess stronger effects than other 25x-NBOMes.

Chemistry

25H-NBOMe or 2C-H-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-H. 25H-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as an iodine atom attached to carbon R4. It differs from 2C-H structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group. 25H-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Pharmacology

Further information: Serotonergic psychedelic

25H-NBOMe has efficacy at the 5-HT2A receptor where it acts as an unusually potent and selective partial agonist.

According to one paper, 25H-NBOMe has stronger affinity than most other members of the NBOMe family.[citation needed]

However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

Among psychedelics, this compound is considered to be pharmacologically unique in terms of the high potency, affinity, and selectivity with which it binds to the 5-HT2a receptor.[citation needed] Contrary to popular belief, it is not a "full agonist"[citation needed], although questions have been raised about how the effects it produces differ from other 5-HT2a partial agonists, which include the range of traditional psychedelics.


Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.


Physical effects

Visual effects

Cognitive effects

Multi-sensory effects

Transpersonal effects

Experience reports

Anecdotal reports which describe the effects of this compound within our experience index include:

Additional experience reports can be found here:

Toxicity and harm potential

Short-term as well as long-term damage of NBOMes have been occasionally tied to serious physical and mental problems on seemingly random people, including memory and speech difficulties, heart problems, HPPD and in some cases Anxiety and PTSD, from particularly difficult experiences.

25H-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined although it is potentially fatal at heavy or very heavy dosages.[2][3] PsychonautWiki advises that due to 25H-NBOMe's extreme potency it should not be insufflated as this method of administration appears to have led to several related deaths in the past year.[4]

The addition of 5-HTP can greatly increase the effects of 25H-NBOME and should be avoided.[citation needed]

It is strongly recommended that one use harm reduction practices when using this substance.

Tolerance and addiction potential

25H-NBOMe is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25H-NBOMe is built almost immediately after ingestion. After that, it takes about 1 week for the tolerance to be reduced to half and 2 weeks to be back at baseline (in the absence of further consumption). 25H-NBOMe presents cross-tolerance with [[Cross-tolerance::all psychedelics]], meaning that after the consumption of 25H-NBOMe all psychedelics will have a reduced effect.

Overdose

Due to the very high potency and seemingly unpredictable effects the margin between a normal and an overdose of NBOMe compounds is extremely small when compared to many other substances. The exact toxic dose is unclear since it seems to depend a lot on personal physiology, rather than predominantly dose. However, various anecdotal reports suggest that dangerous side effects begin to appear when exceeding 1000 μg and it possibly becoming lethal for the more sensitive people at roughly 2000 μg. Reports of other people surviving much higher doses, sometimes even without any major side effects have been documented as well.

There is also the uncertainty of dosage on blotter paper since it is rather difficult to lay such an exact dosage. Insufflating, vaporizing or drinking tinctures of this substance is highly discouraged because of this and has been tied to many documented deaths[1][5][6]. One study found that 25I‐NBOMe and 25C‐NBOMe blotter papers contained 'hotspots' with higher quantities of the drug, implying an inherent risk of overdosing.[7]

The overdose effects of NBOMes are typically a dangerously high heart rate, blood pressure, hyperthermia and significant vasoconstriction[8][9] also accompanied by confusion, delusions, panic attacks, aggressive behavior, numbness or pain, amnesia and often seizures. The risks in an overdose include anything from organ failure to cardiac arrest and death[citation needed]. There are also multiple reports of people lethally injuring themselves or falling to death[10][11]. Benzodiazepines or antipsychotics can help with the psychological effects during an overdose although medical attention should always be called in even a possible overdose of 25I-NBOMe.

Dangerous interactions

This dangerous interactions section is a stub.

As such, it may contain incomplete or invalid information. You can help by expanding upon or correcting it.

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit. Due to the highly unpredictable nature of the NBOMe series, it is generally advised to avoid mixing them with other psychoactive substances.

  • 2C-T-X - The 2C-T-X phenethylamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. As a result, this combination should be avoided.
  • 5-MeO-xxt - The 5-MeO tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. As a result, this combination should be avoided.
  • Amphetamines - Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
  • aMT
  • Caffeine - Caffeine can bring out the natural stimulation from psychedelic drugs to make it uncomfortable. High doses can cause anxiety which is hard to handle while tripping.
  • Cannabis - Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
  • Cocaine - Cocaine and NBOMes both provide considerable stimulation. When combined they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
  • DOx
  • DXM
  • Lithium - Lithium is commonly prescribed in the treatment of [https://en.wikipedia.org/wiki/Bipolar_disorder bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
  • MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably.
  • MDMA
  • MXE - As an NMDA antagonist, MXE potentiates NBOMes which can be unpleasantly intense.
  • Tramadol - Tramadol is well known to lower seizure threshold and NBOMes have also shown a tendency to cause severe seizures
  • Canada: 25H-NBOMe would be considered Schedule III as it is a derivative of 2,5-dimethoxyphenethylamine.[12]
  • Switzerland: 25H-NBOMe is a controlled substance defined as a derivative of N-benzylphenethylamine under Verzeichnis E point 130 and 131.[13]
  • United Kingdom: 25H-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[14]
  • United States: 25H-NBOMe can be controlled under the Federal Analog act.

See also

References

  1. 1.0 1.1 Erowid 25I-NBOMe (2C-I-NBOMe) Vault : Fatalities / Deaths 
  2. "Fatalities / Deaths". Erowid. April 26, 2013. Retrieved 7 May 2013. | http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome_death.shtml
  3. https://erowid.org/chemicals/nbome/nbome_death.shtml
  4. http://www.erowid.org/chemicals/2ci_nbome/2ci_nbome.shtml/
  5. Erowid 2C-C-NBOMe (25C-NBOMe) Vault : Fatalities / Deaths 
  6. Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault : Fatalities / Deaths 
  7. Lützen, E., Holtkamp, M., Stamme, I., Schmid, R., Sperling, M., Pütz, M., Karst, U. (April 2020). "Multimodal imaging of hallucinogens 25C‐ and 25I‐NBOMe on blotter papers". Drug Testing and Analysis. 12 (4): 465–471. doi:10.1002/dta.2751. ISSN 1942-7603. 
  8. Marchi, N. C., Scherer, J. N., Fara, L. S., Remy, L., Ornel, R., Reis, M., Zamboni, A., Paim, M., Fiorentin, T. R., Wayhs, C. A. Y., Von Diemen, L., Pechansky, F., Kessler, F. H. P., Limberger, R. P. (1 March 2019). "Clinical and Toxicological Profile of NBOMes: A Systematic Review". Psychosomatics. 60 (2): 129–138. doi:10.1016/j.psym.2018.11.002. ISSN 0033-3182. 
  9. Yoon, K. S., Yun, J., Kim, Y.-H., Shin, J., Kim, S. J., Seo, J.-W., Hyun, S.-A., Suh, S. K., Cha, H. J. (1 April 2019). "2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo". Toxicology Letters. 304: 50–57. doi:10.1016/j.toxlet.2019.01.004. ISSN 0378-4274. 
  10. https://psychonautwiki.org/wiki/File:Nbome_death_news_i2013e0190_disp.jpg
  11. https://psychonautwiki.org/wiki/File:Nbome_death_news_i2013e0191_disp.jpg
  12. Controlled Drugs and Substances Act (S.C. 1996, c. 19) |http://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-12.html#h-28
  13. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in Deutsch). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  14. United Kingdom. (2014). Misuse of Drugs Act 1971 (S.I. 2014/1106). London: The Stationery Office Limited. Retrieved July 5, 2017, from http://www.legislation.gov.uk/uksi/2014/1106/made